At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years at consent
- ✓Diagnosis of primary liver malignancy (HCC or cholangiocarcinoma) or liver metastasis from solid tumor, confirmed by imaging, clinical presentation, or pathology
- ✓For liver metastases: at least one factor affecting liver function (prior resection, cirrhosis, fatty liver, hepatic insufficiency, or prior upper abdominal radiation/radioembolization)
- ✓ECOG Performance Status 0-2
- ✕Pregnant or planning pregnancy; women of childbearing potential must have negative pregnancy test
- ✕Chemotherapy within 2 weeks of first day of RT
- ✕More than 3 lesions to be treated; maximum sum of diameters ≤6 cm
- ✕Uncontrolled intercurrent illness: ongoing/active infection requiring systemic antibiotics, active upper GI ulceration/hemorrhage, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness limiting compliance
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy
In Brief
A clinical study evaluating Hepatobiliary Iminodiacetic Acid (HIDA) scan for Liver Cancer and 2 related conditions. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to compare radiation treatment plans that are designed for patients with liver cancer. One treatment plan will be created using routine procedures and scans normally performed for radiation treatment planning. The other treatment plan will be created using routine procedures with the addition of two imaging scans; a HIDA (Hepatobiliary Iminodiacetic Acid) scan and an MRI (Magnetic Resonance Imaging) scan. This study will evaluate if adding these imaging scans to treatment planning can reduce the amount of radiation to healthy liver tissue during treatment.
Study Details
Timeline
Interventions
HIDA scan was used as the planning scan for SBRT.